// App-Quantinova.ai

: A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).

Researchers

Presenter

  • T.R. Jeffry Evans

Principal Investigators

  • Richard Hubner

  • Yuk Ting Ma

  • Tim Meyer

  • Daniel H. Palmer

  • David J. James Pinato

  • Elizabeth Ruth Plummer

  • Paul J. Ross

  • Adel Samson

  • Debashis Sarker

  • Timothy Kendall

  • Christopher Bellamy

  • Helen L Reeves

  • Fiona Thomson

  • Claire A Lawless

  • Jamie Stobo

  • Owen J Sansom

  • Derek A. Mann

  • Thomas G Bird

Medical Centers

  • The University of Edinburgh, Edinburgh, United Kingdom

  • University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Kings College London, London, United Kingdom

  • Astra Zeneca, Cambridge, United Kingdom

  • Department of Oncology, UCL Cancer Institute, University College, London & Department of Oncology, Royal Free Hospital London, London, United Kingdom

  • Department of Pathology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

  • Translational and Clinical Research Institute,Newcastle University,Newcastle upon Tyne,Regno Unito

  • Cancer Research UK Clinical Trials Unit, University of Glasgow, Glasgow, United Kingdom

  • Leeds Beckett University, Leeds, United Kingdom

  • CR-UK Beatson Institute & MRC Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, Glasgow, United Kingdom

  • Medical Oncology Department, The Christie NHS Foundation Trust, Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom

  • Newcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Imperial College, London, United Kingdom

  • Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • University of Liverpool, Liverpool, United Kingdom

  • Beatson Institute, Glasgow, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 4

  • C-X-C motif chemokine receptor 2

  • Cluster of differentiation 69

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

  • Circulating DNA

Drug/Treatment

  • Durvalumab

  • Methadone hydrochloride

  • AZD-5069

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • University of Glasgow and NHS Greater Glasgow &amp

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved